Methyldopa
Aldoclor, Aldoril, Methyldopa (methyldopa) is a small molecule pharmaceutical. Methyldopa was first approved as Aldoclor-150 on 1982-01-01. It is used to treat hypertension in the USA. It is known to target aromatic-L-amino-acid decarboxylase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Methyldopa (discontinued: Aldomet, Methyldopa)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorothiazide
+
Methyldopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALDOCLOR-150 | Merck & Co | N-016016 DISCN | 1982-01-01 | 1 products |
| ALDOCLOR-250 | Merck & Co | N-016016 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Methyldopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| METHYLDOPA | Chartwell Pharmaceuticals | N-018934 DISCN | 1984-06-29 | 2 products |
| ALDOMET | Merck & Co | N-013400 DISCN | 1982-01-01 | 3 products, RLD |
| ALDOMET | Merck & Co | N-018389 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Hydrochlorothiazide
+
Methyldopa
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALDORIL 15 | Merck & Co | N-013402 DISCN | 1982-01-01 | 1 products |
| ALDORIL 25 | Merck & Co | N-013402 DISCN | 1982-01-01 | 1 products |
| ALDORIL D30 | Merck & Co | N-013402 DISCN | 1982-01-01 | 1 products |
| ALDORIL D50 | Merck & Co | N-013402 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| methyldopa | ANDA | 2025-03-28 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C02: Antihypertensives
— C02A: Antiadrenergic agents, centrally acting
— C02AB: Methyldopa, centrally acting adntiadrenergic agents
— C02AB01: Methyldopa (levorotatory)
— C02AB02: Methyldopa (racemic)
— C02L: Antihypertensives and diuretics in combination
— C02LB: Methyldopa and diuretics in combination
— C02LB01: Methyldopa (levorotatory) and diuretics
HCPCS
Code | Description |
|---|---|
| J0210 | Injection, methyldopate hcl, up to 250 mg |
Clinical
Clinical Trials
100 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 14 | 18 | 5 | 7 | 3 | 43 |
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 2 | — | 4 | 4 | 11 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 1 | 2 | — | 5 | 3 | 10 |
| Pregnancy-induced hypertension | D046110 | — | O13 | 1 | 1 | — | 3 | 3 | 7 |
| Eclampsia | D004461 | — | O15 | — | — | — | 3 | 2 | 5 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | 1 | — | 1 | 1 | 4 |
| Depression | D003863 | — | F33.9 | — | 1 | — | 1 | — | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | 1 | — | 1 | — | 2 |
| Impulse control disruptive and conduct disorders | D007174 | — | F63.2 | — | — | 1 | 1 | — | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyskinesias | D020820 | — | G24 | 1 | 3 | 1 | — | — | 4 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | 2 | 1 | 1 | — | — | 3 |
| Primary dysautonomias | D054969 | — | — | 2 | 1 | 1 | — | — | 3 |
| Syndrome | D013577 | — | — | 2 | 1 | 1 | — | — | 3 |
| Orthostatic intolerance | D054971 | — | — | 2 | 1 | 1 | — | — | 3 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 2 | 2 | — | — | 2 |
| Familial dysautonomia | D004402 | Orphanet_1764 | G90.1 | — | 1 | 1 | — | — | 2 |
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | 1 | 1 | 1 | — | — | 2 |
| Tachycardia | D013610 | — | R00.0 | 1 | 1 | 1 | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nervous system diseases | D009422 | — | G00-G99 | 2 | 3 | — | — | — | 4 |
| Central nervous system diseases | D002493 | — | G96.9 | — | 3 | — | — | — | 3 |
| Movement disorders | D009069 | EFO_0004280 | G25 | — | 3 | — | — | — | 3 |
| Fatigue | D005221 | — | R53.83 | 2 | 1 | — | — | — | 3 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | 1 | 3 |
| Brain diseases | D001927 | — | G93.40 | — | 2 | — | — | — | 2 |
| Neurodegenerative diseases | D019636 | EFO_0005772 | G31.9 | — | 2 | — | — | — | 2 |
| Shy-drager syndrome | D012791 | EFO_1001050 | — | 2 | 1 | — | — | — | 2 |
| Multiple system atrophy | D019578 | — | — | 2 | 1 | — | — | — | 2 |
| Cocaine-related disorders | D019970 | — | F14 | 1 | 1 | — | — | — | 2 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Pure autonomic failure | D054970 | — | — | 3 | — | — | — | — | 3 |
| Hypotension | D007022 | EFO_0005251 | I95 | 2 | — | — | — | — | 2 |
| Orthostatic hypotension | D007024 | — | I95.1 | 2 | — | — | — | — | 2 |
| Lewy body disease | D020961 | EFO_0006792 | G31.83 | 1 | — | — | — | — | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Disease progression | D018450 | — | — | 1 | — | — | — | — | 1 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | 1 | — | — | — | — | 1 |
| Smoking | D012907 | EFO_0004318 | — | 1 | — | — | — | — | 1 |
Show 5 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Memory consolidation | D000069077 | — | — | — | — | — | — | 1 | 1 |
| Hellp syndrome | D017359 | EFO_0007297 | O14.2 | — | — | — | — | 1 | 1 |
| Transcranial magnetic stimulation | D050781 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methyldopa |
| INN | methyldopa |
| Description | Alpha-methyl-L-dopa is a derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring. It has a role as a hapten, an antihypertensive agent, an alpha-adrenergic agonist, a peripheral nervous system drug and a sympatholytic agent. It is a L-tyrosine derivative and a non-proteinogenic L-alpha-amino acid. |
| Classification | Small molecule |
| Drug class | dopamine receptor agonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 555-30-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL459 |
| ChEBI ID | 61058 |
| PubChem CID | 38853 |
| DrugBank | DB00968 |
| UNII ID | M4R0H12F6M (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
DDC
DDC
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Methyldopa
+
Chlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Methyldopa
+
Hydrochlorothiazide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Methyldopa
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,189 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,522 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use